LE WE PMID CA
Prostate (Neoplasia)2299Prostata (Neubildung)

17 alpha hydroxylase 17 20 lyase

3 methyladenosine ttAutophagy

5T4 Oncotrophoblast glycoprotein

Abiraterone

Aconitase

alpha Methylacyl coenzyme A racemase

AMACR

Apoptosis

ATG5

ATG6 Beclin1

Autophagy

Bisphosphonates

BTP2 3 5 bis trifluoromethyl pyrazole derivative ttTRPC3 ttTRPC5

Cabazitaxel

Calcium (Capacitative transport)

Cardiovascular risk

Cell stress (ER stress)

Ceramide

Citric acid cycle

Colon and rectum (Neoplasia)

Curcumin

CYP17

Degarelix

Docetaxel

Econazole

Endothelin

FoxA2

GOLM1

Goserelin acetate

GSTP1 1

HIF1alpha und HIF1 (BASKET)

hVps34

IK Ca1

Immunotherapy (Adoptive cell transfer)

Interleukin24 MDA7

Interleukin32

Ion channel (Potassium)

Ion channel (TRP Family)

JAK STAT

Kidney (Neoplasia RCC)

Kidney (Neoplasm)

Klf4

Leuprorelin

LHRH

Lynch syndrome

MiRNA 205

Neoplasia (Carcinogenesis)

Neoplasia (Oncolytic virus)

Neoplasia (Screening)

Neoplasia (Tumor biology and immunology)

Neoplasia (Tumor markers)

NFAT

PCA3

Polycyclic aromatic hydrocarbons

Prostate (Anatomy)

Prostate (BASKET)

Prostate (Development)

Prostate (MRS)

Prostate (MRT)

Prostate (Neoplasia)

Prostate (Sonography)

Prostatic acid phosphatase

Radiation therapy

Radiopharmacology

Receptor (Estrogen)

Receptor (GnRH)

Rhinosporidiosis

RNA (MicroRNA)

Satraplatin

SIAH2

Sipuleucel T

Skin (Neoplasia Melanoma)

Stem cell (Neoplasia)

TMPRSS2

Transglutaminase4

Transporter (Zinc)

TRPC6

TRPM1

TRPM8

TRPV2

TRPV6

Ultrasound (Toxicity and therapeutic use)

Vaccine (Oncology)

Vanilloids

Vitamin D

Wnt beta Catenin TCF

ZD4054 ttET1RA

Zinc

ZIP1

2009  
1
Degarelix and its therapeutic potential in the treatment of prostate cancer.
[19503784] Clin Interv Aging 4(-): 215-23 (2009)
2006  
2
Role of 5 alpha-reductase inhibitors in the management of prostate cancer.
[18046919] Clin Interv Aging 1(4): 425-31 (2006)
2008  
3
The top 13: what family physicians should know about prostate cancer.
[18272635] Can Fam Physician 54(2): 198-203 (2008)
2009  
4
Active surveillance or active treatment in localized prostate cancer?
[19623304] Dtsch Arztebl Int 106(22): 371-6 (2009)
2009  
5
Hormonal therapy in the elderly prostate cancer patient.
[19547640] Dtsch Arztebl Int 106(14): 242-7 (2009)
1995  
6
Prostatic intraepithelial neoplasia: a potential precursor lesion of prostatic adenocarcinoma.
[7660673] Yonsei Med J 36(3): 215-31 (1995)
2008  
7
Leuprorelin depot injection: patient considerations in the management of prostatic cancer.
[18728847] Ther Clin Risk Manag 4(2): 513-26 (2008)
2007  
8
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.
[18473011] Ther Clin Risk Manag 3(5): 877-83 (2007)
2009  
9
Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.
[19128541] Health Technol Assess 13(5): iii, xi-xiii 1-219 (2009)
2007  
10
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
[17181985] Health Technol Assess 11(2): iii-iv, xv-xviii, 1-179 (2007)
2006  
11
Prostate cancer treatment. The case for radical prostatectomy.
[17002843] Ann R Coll Surg Engl 88(5): 439-42 (2006)
2005  
12
Rectal infiltration by prostatic adenocarcinoma: a report on six patients and review of the literature.
[15720916] Ann R Coll Surg Engl 87(1): 72-3 (2005)
1953  
13
Benign nodular hyperplasia of the prostate; a review.
[13125240] Ann R Coll Surg Engl 14(2): 92-106 (1953)
2009  
14
Stroma-epithelium crosstalk in prostate cancer.
[19098934] Asian J Androl 11(1): 28-35 (2009)
2009  
15
Prostate cancer: diagnosis and staging.
[19050692] Asian J Androl 11(1): 74-80 (2009)
2009  
16
Management of locally advanced prostate cancer.
[19050683] Asian J Androl 11(1): 81-7 (2009)
2010  
17
Androgen receptor signaling and mutations in prostate cancer.
[20711217] Asian J Androl 12(5): 639-57 (2010)
1997  
18
Prostate cancer: a clinical and basic science review.
[9089063] J Androl 18(1): 15-20 (1997)
1991  
19
Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
[1769904] J Androl 12(6): 364-71 (1991)
1991  
20
The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia.
[1722795] J Androl 12(6): 389-94 (1991)
1991  
21
The pathophysiology of benign prostatic hyperplasia.
[1722791] J Androl 12(6): 356-63 (1991)
1991  
22
The origin and development of benign prostatic hyperplasia. An age-dependent process.
[1722790] J Androl 12(6): 348-55 (1991)
2008  
23
Clinical utility of prostate carcinoma molecular diagnostic tests.
[18470278] Rev Urol 10(1): 44-69 (2008)
2006  
24
Treatment- and disease-related complications of prostate cancer.
[17021643] Rev Urol 8 Suppl 2(-): S56-67 (2006)
2005  
25
Addressing the needs of the high-risk prostate cancer patient.
[16985880] Rev Urol 7 Suppl 5(-): S18-28 (2005)
2005  
26
Maximum androgen blockade: a clinical update.
[16985879] Rev Urol 7 Suppl 5(-): S13-7 (2005)
2004  
27
A critical review of maximal androgen blockade for advanced prostate cancer.
[16985916] Rev Urol 6 Suppl 8(-): S18-23 (2004)
2009  
28
Brachytherapy for prostate cancer: a systematic review.
[19730753] Adv Urol -(-): 327945 (2009)
2009  
29
Modalities for imaging of prostate cancer.
[20339583] Adv Urol -(-): 818065 (2009)
1998  
30
Malignant changes in the prostate with ageing.
[9883262] Br J Urol 82 Suppl 1(-): 47-58 (1998)
1997  
31
The concept of evolution in the pathogenesis and treatment of prostate cancer.
[9126065] Br J Urol 79 Suppl 2(-): 9-17 (1997)
2008  
32
Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.
[18953438] Neoplasia 10(11): 1285-94 (2008)
2007  
33
Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.
[17603627] Neoplasia 9(6): 455-63 (2007)
2006  
34
Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.
[17576447] Curr Oncol 13(3): 81-93 (2006)
2010  
35
Update on options for treatment of metastatic castration-resistant prostate cancer.
[20616956] Onco Targets Ther 3(-): 39-51 (2010)
2008  
36
Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[18456765] Ann Oncol 19 Suppl 2(-): ii45-6 (2008)
2004  
37
2002  
38
Treatment options in hormone resistant prostate cancer.
[12401673] Ann Oncol 13 Suppl 4(-): 95-102 (2002)
2002  
39
Prostate cancer: management of advanced disease.
[12401672] Ann Oncol 13 Suppl 4(-): 89-94 (2002)
2002  
40
Management of early prostate cancer.
[12401671] Ann Oncol 13 Suppl 4(-): 83-7 (2002)
2008  
41
Management of complications of prostate cancer treatment.
[18502900] CA Cancer J Clin 58(4): 196-213 (2008)
2002  
42
The current state of hormonal therapy for prostate cancer.
[12018929] CA Cancer J Clin 52(3): 154-79 (2002)
2000  
43
External beam radiation therapy for prostate cancer.
[11146903] CA Cancer J Clin 50(6): 349-75; quiz 376-9 (2000)
2000  
44
1999  
45
Contemporary results of anatomic radical prostatectomy.
[11198955] CA Cancer J Clin 49(5): 282-96 (1999)
1995  
46
Brachytherapy for prostate cancer.
[7743420] CA Cancer J Clin 45(3): 165-78 (1995)
2008  
47
An updated catalog of prostate cancer predictive tools.
[18823041] Cancer 113(11): 3075-99 (2008)
2007  
48
Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate.
[17420979] Cancer 109(10): 2011-5 (2007)
2007  
49
The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review.
[17123267] Cancer 109(1): 13-24 (2007)
2005  
50
Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues.
[16007687] Cancer 104(5): 891-905 (2005)
2004  
51
Human prostate cancer risk factors.
[15495199] Cancer 101(10 Suppl): 2371-490 (2004)
2000  
52
Novel strategies and therapeutics for the treatment of prostate carcinoma.
[11002230] Cancer 89(6): 1329-48 (2000)
1997  
53
The natural history of clinical prostate carcinoma.
[9307180] Cancer 80(5): 827-33 (1997)
2010  
54
Promoter hypermethylation in prostate cancer.
[20861812] Cancer Control 17(4): 245-55 (2010)
2010  
55
Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window.
[20861810] Cancer Control 17(4): 223-32 (2010)
2010  
56
Premalignant and malignant prostate lesions: pathologic review.
[20861809] Cancer Control 17(4): 214-22 (2010)
2007  
57
High-intensity focused ultrasound (HIFU) for prostate cancer.
[17615530] Cancer Control 14(3): 244-9 (2007)
2007  
58
Modern brachytherapy for treatment of prostate cancer.
[17615529] Cancer Control 14(3): 238-43 (2007)
2007  
59
Review of primary and salvage cryoablation for prostate cancer.
[17615528] Cancer Control 14(3): 231-7 (2007)
2006  
60
Novel agents and targets in managing patients with metastatic prostate cancer.
[16885915] Cancer Control 13(3): 194-8 (2006)
2006  
61
The role of external-beam radiation therapy in the treatment of clinically localized prostate cancer.
[16885914] Cancer Control 13(3): 188-93 (2006)
2004  
62
Management of androgen-independent prostate cancer.
[15625524] Cancer Control 11(6): 364-73 (2004)
2001  
63
Prostate adenocarcinoma: cellular and molecular abnormalities.
[11807425] Cancer Control 8(6): 551-61 (2001)
2001  
64
NCCN: New chemotherapeutic approaches to hormone refractory prostate cancer.
[11760560] Cancer Control 8(6 Suppl 2): 62-5 (2001)
2001  
65
The evolving role of prostate brachytherapy.
[11326171] Cancer Control 8(2): 163-70 (2001)
2001  
66
Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer.
[11326168] Cancer Control 8(2): 141-50 (2001)
2006  
67
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.
[16195239] Carcinogenesis 27(1): 1-22 (2006)
2005  
68
Prostate carcinogenesis and inflammation: emerging insights.
[15498784] Carcinogenesis 26(7): 1170-81 (2005)
1994  
69
Prostate cancer progression. Implications of histopathology.
[7977655] Am J Pathol 145(5): 983-93 (1994)
2000  
70
Hormonal therapy for advanced prostate cancer.
[10744596] Ann Intern Med 132(7): 584-5 (2000)
2000  
71
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
[10744594] Ann Intern Med 132(7): 566-77 (2000)
2007  
72
Early versus delayed endocrine therapy for prostate cancer.
[17395971] Endocr Relat Cancer 14(1): 1-11 (2007)
2005  
73
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
[15947099] Endocr Relat Cancer 12(2): 229-44 (2005)
2004  
74
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
[15369448] Endocr Relat Cancer 11(3): 459-76 (2004)
1999  
75
Neuroendocrine cells in tumour growth of the prostate.
[10730904] Endocr Relat Cancer 6(4): 503-19 (1999)
1999  
76
Prostate cancer: molecular biology of early progression to androgen independence.
[10730903] Endocr Relat Cancer 6(4): 487-502 (1999)
2000  
77
Molecular genetics of prostate cancer.
[11018010] Genes Dev 14(19): 2410-34 (2000)
2008  
78
Approach to the prostate cancer patient with bone disease.
[18178905] J Clin Endocrinol Metab 93(1): 2-7 (2008)
2001  
79
Clinical review 134: The endocrinology of prostate cancer.
[11502765] J Clin Endocrinol Metab 86(8): 3467-77 (2001)
2005  
80
Molecular pathology of prostate cancer.
[15976331] J Clin Pathol 58(7): 673-84 (2005)
2005  
81
Androgen deprivation therapy for prostate cancer.
[16014598] JAMA 294(2): 238-44 (2005)
2008  
82
High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer.
[19046556] Mayo Clin Proc 83(12): 1364-72 (2008)
2005  
83
Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease.
[16007895] Mayo Clin Proc 80(7): 899-907 (2005)
2005  
84
External beam radiotherapy as curative treatment of prostate cancer.
[16007894] Mayo Clin Proc 80(7): 883-98 (2005)
2004  
85
Tissue ablation technologies for localized prostate cancer.
[15595340] Mayo Clin Proc 79(12): 1547-55 (2004)
2004  
86
Minimally invasive radical prostatectomy.
[15357040] Mayo Clin Proc 79(9): 1169-80 (2004)
2004  
87
Unusual subtypes of prostate cancer.
[14976541] Mod Pathol 17(3): 316-27 (2004)
2004  
88
Gleason grading and prognostic factors in carcinoma of the prostate.
[14976540] Mod Pathol 17(3): 292-306 (2004)
2004  
89
Benign mimickers of prostatic adenocarcinoma.
[14976539] Mod Pathol 17(3): 328-48 (2004)
2004  
90
Radical prostatectomy for carcinoma of the prostate.
[14765206] Mod Pathol 17(3): 349-59 (2004)
2004  
91
Molecular genetics of human prostate cancer.
[14752525] Mod Pathol 17(3): 380-8 (2004)
2004  
92
High-grade prostatic intraepithelial neoplasia.
[14739906] Mod Pathol 17(3): 360-79 (2004)
2009  
93
Multidisciplinary functional MR imaging for prostate cancer.
[19885309] Korean J Radiol 10(6): 535-51 (2009)
2008  
94
Novel tracers and their development for the imaging of metastatic prostate cancer.
[18997047] J Nucl Med 49(12): 2031-41 (2008)
2003  
95
PET imaging of prostate cancer with 11C-acetate.
[12679399] J Nucl Med 44(4): 556-8 (2003)
2007  
96
Functional MR imaging of prostate cancer.
[17234999] Radiographics 27(1): 63-75; discussion 75-7 (2007)
2004  
97
Complications of prostate cancer treatment: spectrum of imaging findings.
[15486240] Radiographics 24 Suppl 1(-): S181-94 (2004)
2004  
98
Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy.
[15486239] Radiographics 24 Suppl 1(-): S167-80 (2004)
2001  
99
Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer.
[11314451] CMAJ 164(7): 975-81 (2001)
1999  
100
1990  
101
Cystic lesions of the prostate.
[1696019] Radiographics 10(4): 635-50 (1990)
2008  
102
Pictorial review: Unusual tumours involving the prostate: radiological-pathological findings.
[18662962] Br J Radiol 81(971): 907-15 (2008)
2007  
103
Imaging prostate cancer: a multidisciplinary perspective.
[17392247] Radiology 243(1): 28-53 (2007)
2006  
104
Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging.
[16569788] Radiology 239(3): 784-92 (2006)
2005  
105
Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
[15867098] Endocr Rev 26(3): 361-79 (2005)
2004  
106
Androgen receptor in prostate cancer.
[15082523] Endocr Rev 25(2): 276-308 (2004)
2009  
107
Vanilloid-mediated apoptosis in prostate cancer cells through a TRPV-1 dependent and a TRPV-1-independent mechanism.
[19705615] Acta Biomed 80(1): 13-20 (2009)
2008  
108
Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer.
[18323866] Acta Med Okayama 62(1): 9-13 (2008)
2011  
109
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
[21757258] Actas Urol Esp 35(10): 565-79 (2011)
2010  
110
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555062] Ann Oncol 21 Suppl 5(-): v129-33 (2010)
2010  
111
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
[19633053] Ann Oncol 21(2): 312-8 (2010)
2010  
112
Horizon scanning for novel therapeutics for the treatment of prostate cancer.
[20943642] Ann Oncol 21 Suppl 7(-): vii43-55 (2010)
2005  
113
Hormonotherapy of advanced prostate cancer.
[15923436] Ann Oncol 16 Suppl 4(-): iv80-84 (2005)
2009  
114
Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[19454471] Ann Oncol 20 Suppl 4(-): 76-8 (2009)
2009  
115
Challenges in clinical prostate cancer: role of imaging.
[19457806] AJR Am J Roentgenol 192(6): 1455-70 (2009)
2009  
116
Imaging localized prostate cancer: current approaches and new developments.
[19457807] AJR Am J Roentgenol 192(6): 1471-80 (2009)
2004  
117
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
[15323145] Am J Clin Pathol 122(2): 275-89 (2004)
2011  
118
Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer.
[21416055] Am J Transl Res 3(2): 133-8 (2011)
2009  
119
Neuroendocrine differentiation in prostate cancer.
[19956427] Am J Transl Res 1(2): 148-62 (2009)
2010  
120
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.
[20843937] BMJ 341(): c4543 (2010)
2011  
121
A practical guide to prostate cancer diagnosis and management.
[21536828] Cleve Clin J Med 78(5): 321-31 (2011)
2010  
122
New developments in the medical management of prostate cancer.
[20042563] Mayo Clin Proc 85(1): 77-86 (2010)
2007  
123
Prostate cancer: a practical approach to current management of recurrent disease.
[17290734] Mayo Clin Proc 82(2): 243-9 (2007)
2007  
124
Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide.
[17507719] Radiology 244(1): 196-204 (2007)
2007  
125
Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.
[17890357] Radiology 245(2): 499-506 (2007)
2008  
126
Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging.
[18024434] Radiology 246(1): 177-84 (2008)
2011  
127
Pseudosarcomatous fibromyxoid tumor of the prostate.
[21552766] ScientificWorldJournal 11(-): 1027-30 (2011)
2011  
128
Methods to predict and lower the risk of prostate cancer.
[21479345] ScientificWorldJournal 11(-): 742-8 (2011)
2010  
129
PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.
[20890581] ScientificWorldJournal 10(-): 1919-31 (2010)
2010  
130
Stereotactic body radiation therapy (SBRT) for genitourinary malignancies.
[20875347] Discov Med 10(52): 255-62 (2010)
2005  
131
Endocrine approaches in the therapy of prostate carcinoma.
[15790600] Hum Reprod Update 11(3): 309-17 (2005)
2010  
132
New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.
[20423984] Clin Cancer Res 16(13): 3322-8 (2010)
2009  
133
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
[19638458] Clin Cancer Res 15(15): 4792-8 (2009)
2009  
134
Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
[19638457] Clin Cancer Res 15(15): 4799-805 (2009)
2009  
135
Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
[19684076] Oncologist 14(8): 816-27 (2009)
2008  
136
Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.
[18278811] Cancer 112(8): 1660-71 (2008)
2006  
137
Treatment options in lymph node-positive prostate cancer.
[16700035] Cancer 106(12): 2531-9 (2006)
2007  
138
Pten inactivation and the emergence of androgen-independent prostate cancer.
[17638861] Cancer Res 67(14): 6535-8 (2007)
2009  
139
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
[19509232] Cancer Res 69(12): 4937-40 (2009)
2009  
140
Concepts of epigenetics in prostate cancer development.
[19002169] Br J Cancer 100(2): 240-5 (2009)
2008  
141
Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
[18927246] Clin Chem 54(12): 1951-60 (2008)
2011  
142
Radical prostatectomy versus watchful waiting in early prostate cancer.
[21542742] N Engl J Med 364(18): 1708-17 (2011)
2010  
143
Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
[21029717] Health Technol Assess 14(47): 1-108, iii-iv (2010)
2009  
144
Molecular mechanisms of castration-resistant prostate cancer progression.
[19903068] Future Oncol 5(9): 1403-13 (2009)
2007  
145
My approach to intraductal lesions of the prostate gland.
[17237185] J Clin Pathol 60(8): 856-65 (2007)
2007  
146
TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.
[17965219] J Clin Pathol 60(11): 1185-6 (2007)
2007  
147
Spindle cell lesions of the adult prostate.
[17170745] Mod Pathol 20(1): 148-58 (2007)
2007  
148
Pathogenesis of prostate cancer and hormone refractory prostate cancer.
[19675761] Indian J Urol 23(1): 35-42 (2007)
2007  
149
Update in palliative management of hormone refractory cancer of prostate.
[19675762] Indian J Urol 23(1): 43-50 (2007)
2007  
150
Use of bisphosphonates in prostate cancer: Current status.
[19675763] Indian J Urol 23(1): 51-4 (2007)
2007  
151
New therapeutic targets in the treatment of prostate cancer.
[19675766] Indian J Urol 23(1): 61-6 (2007)
2007  
152
Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines.
[19675767] Indian J Urol 23(1): 67-9 (2007)
2009  
153
Etiopathogenesis of benign prostatic hypeprlasia.
[19881121] Indian J Urol 25(3): 312-7 (2009)
2010  
154
The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities.
[21037926] Oncotarget 1(5): 379-85 (2010)
2006  
155
Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis.
[16154258] Cancer Lett 239(2): 157-67 (2006)
2011  
156
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
[21149473] J Nucl Med 52(1): 81-9 (2011)
2009  
157
Epigenetic alterations in human prostate cancers.
[19520778] Endocrinology 150(9): 3991-4002 (2009)
2007  
158
Zinc as an anti-tumor agent in prostate cancer and in other cancers.
[17400177] Arch Biochem Biophys 463(2): 211-7 (2007)
2002  
159
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault.
[11914183] Endocr Relat Cancer 9(1): 61-73 (2002)
2011  
160
Pathways of chemotherapy resistance in castration-resistant prostate cancer.
[21565970] Endocr Relat Cancer 18(4): R103-23 (2011)
2010  
161
An update on androgen deprivation therapy for prostate cancer.
[20861285] Endocr Relat Cancer 17(4): R305-15 (2010)
2010  
162
2007  
163
Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
[17914087] Endocr Relat Cancer 14(3): 531-47 (2007)
2006  
164
High-intensity focused ultrasound: a potential salvage treatment for recurrent prostate cancer following radiotherapy.
[16831068] Expert Rev Anticancer Ther 6(7): 969-70 (2006)
2010  
165
MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer.
[20737563] Cancer 116(24): 5637-49 (2010)
2010  
166
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.
[20406981] Cancer Res 70(9): 3667-76 (2010)
2011  
167
Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer.
[21524313] J Transl Med 9(): 49 (2011)
2010  
168
Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach.
[19888195] Mol Ther 18(2): 295-306 (2010)
2011  
169
5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
[21920036] BMC Med 9(-): 105 (2011)
2011  
170
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
[21448449] Drug Des Devel Ther 5(-): 117-24 (2011)
2010  
171
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.
[20138542] Trends Endocrinol Metab 21(5): 315-24 (2010)
2011  
172
Wnt signaling in prostate development and carcinogenesis.
[21475372] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155(1): 11-8 (2011)
2011  
173
TRP channels in prostate cancer: the good, the bad and the ugly?
[21623387] Asian J Androl 13(5): 673-6 (2011)
2003  
174
Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1.
[12584203] J Biol Chem 278(17): 15381-9 (2003)
2001  
175
Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer.
[11278579] J Biol Chem 276(22): 19461-8 (2001)
2004  
176
TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression.
[15336984] Biochem Biophys Res Commun 322(4): 1359-63 (2004)
2007  
177
2006  
178
TRPV6 potentiates calcium-dependent cell proliferation.
[16356545] Cell Calcium 39(2): 163-73 (2006)
2003  
179
Store-operated Ca2+ channels in prostate cancer epithelial cells: function, regulation, and role in carcinogenesis.
[12765682] Cell Calcium 33(5-6): 357-73 (2003)
2011  
180
TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth.
[21347289] PLoS One 6(2): e16856 (2011)
2010  
181
2009  
182
Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry.
[19270724] Oncogene 28(15): 1792-806 (2009)
2007  
183
TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways.
[17533368] Oncogene 26(52): 7380-5 (2007)
2003  
184
Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression.
[14586412] Oncogene 22(49): 7858-61 (2003)
2011  
185
Chemical inhibitors of the calcium entry channel TRPV6.
[21057859] Pharm Res 28(2): 322-30 (2011)
2011  
186
Value of ultrasound elastography in the diagnosis and management of prostate carcinoma.
[21390343] Med Ultrason 13(1): 45-53 (2011)
2011  
187
Real-time ultrasound prostate elastography. An increasing role in prostate cancer detection?
[21390335] Med Ultrason 13(1): 3-4 (2011)
2010  
188
Prostate lesions with cribriform / pseudocribriform pattern.
[20809015] Rom J Morphol Embryol 51(3): 413-25 (2010)
2010  
189
Cellular interactions in prostate cancer genesis and dissemination. Looking beyond the obvious.
[20809016] Rom J Morphol Embryol 51(3): 427-35 (2010)
2010  
190
Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance.
[20191113] Rom J Morphol Embryol 51(1): 7-12 (2010)
2011  
191
A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.
[21874106] Curr Oncol 18(4): e163-72 (2011)
2011  
192
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
[21513551] J Hematol Oncol 4(-): 18 (2011)
2008  
193
Recurrent gene fusions in prostate cancer.
[18563191] Nat Rev Cancer 8(7): 497-511 (2008)
2010  
194
American Cancer Society guideline for the early detection of prostate cancer: update 2010.
[20200110] CA Cancer J Clin 60(2): 70-98 (2010)
2010  
195
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
[20124400] CA Cancer J Clin 60(3): 194-201 (2010)
2009  
196
High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancer.
[19158990] Int J Clin Exp Pathol 2(4): 327-38 (2009)
2009  
197
Molecular markers in prostate cancer. Part II: potential roles in management.
[19050689] Asian J Androl 11(1): 22-7 (2009)
2009  
198
Molecular markers in prostate cancer. Part I: predicting lethality.
[19050690] Asian J Androl 11(1): 14-21 (2009)
2010  
199
Histological changes in the human prostate after radiotherapy and salvage high intensity focused ultrasound.
[20694085] Can Urol Assoc J 4(4): E100-2 (2010)
2011  
200
Emerging novel therapies in the treatment of castrate-resistant prostate cancer.
[21470540] Can Urol Assoc J 5(2): 120-33 (2011)
2011  
201
Prostate cancer screening: Canadian guidelines 2011.
[21801679] Can Urol Assoc J 5(4): 235-40 (2011)
2010  
202
The novel prostate cancer antigen 3 (PCA3) biomarker.
[21176272] Int Braz J Urol 36(6): 665-8; discussion 669 (2010)
2009  
203
T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy.
[19409121] Int Braz J Urol 35(2): 171-80; discussion 181-2 (2009)
2009  
204
Anti-neoplastic activity of curcumin in PCa.
[19538760] Int Braz J Urol 35(3): 254-5 (2009)
2011  
205
Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature.
[21627811] Diagn Pathol 6(-): 46 (2011)
2011  
206
Cardiovascular risk during hormonal treatment in patients with prostate cancer.
[21448299] Cancer Manag Res 3(-): 49-55 (2011)
2011  
207
Chemoprevention of prostate cancer with nutrients and supplements.
[21629831] Cancer Manag Res 3(-): 91-100 (2011)
2010  
208
Evaluation of degarelix in the management of prostate cancer.
[21188095] Cancer Manag Res 2(-): 39-52 (2010)
2009  
209
Update on the management of prostate cancer with goserelin acetate: patient perspectives.
[21188128] Cancer Manag Res 1(-): 99-105 (2009)
2011  
210
Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists.
[21789160] Ther Adv Med Oncol 3(2): 101-8 (2011)
2007  
211
Minimally invasive approaches to prostate cancer: a review of the current literature.
[17987573] Urol J 4(3): 130-7 (2007)
2007  
212
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
[17940447] Curr Opin Endocrinol Diabetes Obes 14(3): 247-54 (2007)
2007  
213
Current standard and investigational approaches to the management of hormone-refractory prostate cancer.
[17387372] Rev Urol 9 Suppl 1(-): S9-S19 (2007)
2007  
214
High-risk, clinically localized prostate cancer: is monotherapy adequate?
[17554402] Rev Urol 9 Suppl 2(-): S19-27 (2007)
2008  
215
ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
[18616419] Expert Opin Investig Drugs 17(8): 1237-45 (2008)
2007  
216
The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer.
[17511871] Radiat Oncol 2(-): 17 (2007)
2011  
217
Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
[22084621] Clin Med Insights Oncol 5(-): 325-32 (2011)
2011  
218
Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.
[21695098] Clin Med Insights Oncol 5(-): 163-9 (2011)
2004  
219
The role of alpha-blockers in the management of prostate cancer.
[15163273] Expert Opin Pharmacother 5(6): 1279-85 (2004)
2010  
220
Angiogenesis inhibitors in the treatment of prostate cancer.
[20088745] Expert Opin Pharmacother 11(2): 233-47 (2010)
2010  
221
Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial.
[20964826] BMC Cancer 10(-): 572 (2010)
2010  
222
Prioritizing genes associated with prostate cancer development.
[21044312] BMC Cancer 10(-): 599 (2010)
2011  
223
Saudi Oncology Society clinical management guidelines for prostate cancer.
[21673847] Urol Ann 3 Suppl(-): S10-6 (2011)
2011  
224
An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.
[21904569] Ther Adv Urol 3(3): 127-40 (2011)
2010  
225
Novel diagnostic biomarkers for prostate cancer.
[20975847] J Cancer 1(-): 150-77 (2010)
2010  
226
Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment.
[20130444] Pharmacology 85(2): 110-20 (2010)
2011  
227
Imaging in prostate cancer diagnosis: present role and future perspectives.
[21372554] Urol Int 86(4): 373-82 (2011)
2011  
228
Current treatment strategies for castration-resistant prostate cancer.
[21461278] Korean J Urol 52(3): 157-65 (2011)
2010  
229
Radical prostatectomy for high-risk prostate cancer.
[19841101] Jpn J Clin Oncol 40(1): 3-9 (2010)
2009  
230
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
[19318948] Curr Opin Urol 19(3): 221-6 (2009)
2009  
231
Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.
[19434102] Nat Rev Urol 6(6): 317-23 (2009)
2009  
232
Management of complications of androgen deprivation therapy in the older man.
[18952456] Crit Rev Oncol Hematol 70(3): 235-55 (2009)
2008  
233
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
[18280514] J Urol 179(4): 1235-42 (2008)
2007  
234
Low risk prostate cancer in men under age 65: the case for definitive treatment.
[18047962] Urol Oncol 25(6): 510-4 (2007)
2009  
235
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.
[19414113] Urol Oncol 27(3): 251-7 (2009)
2009  
236
Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens.
[19414117] Urol Oncol 27(3): 301-3 (2009)
2011  
237
Overall and worst gleason scores are equally good predictors of prostate cancer progression.
[21978318] BMC Urol 11(-): 21 (2011)
2009  
238
A systematic review of the diagnostic accuracy of prostate specific antigen.
[19744336] BMC Urol 9(-): 14 (2009)
2010  
239
A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.
[19496018] Int Urol Nephrol 42(1): 29-38 (2010)
2009  
240
New horizons in prostate cancer imaging.
[18993004] Eur J Radiol 70(2): 212-26 (2009)
2009  
241
Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis.
[18952365] Eur Urol 55(3): 575-90 (2009)
2011  
242
Hereditary prostate cancer as a feature of Lynch syndrome.
[20872076] Fam Cancer 10(1): 37-42 (2011)
2011  
243
Screening for prostate cancer: the current evidence and guidelines controversy.
[22018148] Can J Urol 18(5): 5875-83 (2011)
2009  
244
New therapeutic agents for castration-refractory prostate cancer.
[19692323] Clin Genitourin Cancer 7(2): E4-6 (2009)
2009  
245
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
[19796750] Lancet Oncol 10(10): 981-91 (2009)
2008  
246
The discovery and application of gene fusions in prostate cancer.
[18422767] BJU Int 102(3): 276-82 (2008)
2011  
247
Role of signaling transduction pathways in development of castration-resistant prostate cancer.
[22110995] Prostate Cancer 2011(-): 647987 (2011)
2009  
248
The role of androgen receptor mutations in prostate cancer progression.
[19721807] Curr Genomics 10(1): 18-25 (2009)
2011  
249
Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.
[21504942] J Mol Endocrinol 47(1): R25-41 (2011)
2008  
250
The role of estrogens and estrogen receptors in normal prostate growth and disease.
[18093629] Steroids 73(3): 233-44 (2008)
2011  
251
An update on TroVax for the treatment of progressive castration-resistant prostate cancer.
[21691576] Onco Targets Ther 4(-): 33-41 (2011)
2011  
252
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.
[21792315] Onco Targets Ther 4(-): 79-96 (2011)
2010  
253
Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis.
[20501771] Cancer Epidemiol Biomarkers Prev 19(6): 1632-42 (2010)
2010  
254
Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration.
[21159640] Cancer Res 70(24): 10182-91 (2010)
2011  
255
Targeting tyrosine kinases and autophagy in prostate cancer.
[21350583] Horm Cancer 2(1): 38-46 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia